IN2014KN03063A - - Google Patents

Info

Publication number
IN2014KN03063A
IN2014KN03063A IN3063KON2014A IN2014KN03063A IN 2014KN03063 A IN2014KN03063 A IN 2014KN03063A IN 3063KON2014 A IN3063KON2014 A IN 3063KON2014A IN 2014KN03063 A IN2014KN03063 A IN 2014KN03063A
Authority
IN
India
Prior art keywords
vaccine composition
administration
administration regimens
polynucleotides
enhance
Prior art date
Application number
Inventor
Alfredo Nicosia
Ricardo Cortese
Alessandra Vitelli
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of IN2014KN03063A publication Critical patent/IN2014KN03063A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to administration regimens which are particularly suited for vaccine composition comprising polynucleotides which encode immunogenic polypeptides. Said administration regimens involve the repeated administration of a vaccine composition and enhance the immune response against the immunogenic polypeptide.
IN3063KON2014 2012-07-05 2013-07-05 IN2014KN03063A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2012/063196 WO2014005643A1 (en) 2012-07-05 2012-07-05 Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
PCT/EP2013/064286 WO2014006191A1 (en) 2012-07-05 2013-07-05 Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides

Publications (1)

Publication Number Publication Date
IN2014KN03063A true IN2014KN03063A (en) 2015-05-08

Family

ID=48746554

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3063KON2014 IN2014KN03063A (en) 2012-07-05 2013-07-05

Country Status (19)

Country Link
US (3) US20150209420A1 (en)
JP (1) JP6244358B2 (en)
KR (1) KR20150038010A (en)
CN (1) CN104780937A (en)
AU (1) AU2013285398A1 (en)
BR (1) BR112014033077A2 (en)
CA (1) CA2878367A1 (en)
DK (1) DK2869841T3 (en)
EA (1) EA201492230A1 (en)
ES (1) ES2895070T3 (en)
HU (1) HUE056675T2 (en)
IL (1) IL236414A0 (en)
IN (1) IN2014KN03063A (en)
LT (1) LT2869841T (en)
MX (1) MX365391B (en)
PT (1) PT2869841T (en)
SG (1) SG11201408746XA (en)
WO (2) WO2014005643A1 (en)
ZA (1) ZA201500102B (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6469081B2 (en) 2013-04-25 2019-02-13 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Stabilized soluble pre-fusion RSVF polypeptide
JP6664338B2 (en) * 2014-06-13 2020-03-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Immunogenic combination
SG11201701745TA (en) 2014-09-03 2017-04-27 Bavarian Nordic As Methods and compositions for enhancing immune responses
JP6462861B2 (en) 2014-09-03 2019-01-30 バヴァリアン ノルディック エー／エス Methods and compositions aimed at inducing protective immunity against filovirus infection
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
MX2017014538A (en) 2015-05-15 2018-03-02 Curevac Ag Prime-boost regimens involving administration of at least one mrna construct.
WO2017005848A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f polypeptides
US10456462B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Preventions B.V. Vaccine against RSV
PL3439672T3 (en) 2016-04-05 2021-06-14 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f protein for use in the prophylaxis of rsv infection
MX2018012095A (en) 2016-04-05 2019-01-10 Janssen Vaccines & Prevention Bv Vaccine against rsv.
CN109922829A (en) * 2016-05-02 2019-06-21 扬森疫苗与预防公司 Therapeutic HPV vaccine combination
MX2018014699A (en) 2016-05-30 2019-02-28 Janssen Vaccines & Prevention Bv Stabilized pre-fusion rsv f proteins.
WO2018011768A1 (en) 2016-07-15 2018-01-18 Janssen Vaccines And Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
BR112019020661A2 (en) 2017-04-04 2020-05-05 University Of Washington self-assembling protein nanostructures that exhibit paramyxovirus and / or pneumovirus f proteins and their use
EP3606553A1 (en) 2017-04-06 2020-02-12 Janssen Vaccines & Prevention B.V. Mva-bn and ad26.zebov or ad26.filo prime-boost regimen
WO2018210871A1 (en) * 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
AU2018267971A1 (en) 2017-05-17 2019-11-07 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
MX2020002876A (en) 2017-09-15 2020-07-22 Janssen Vaccines & Prevention Bv Method for the safe induction of immunity against rsv.
MX2020004305A (en) * 2017-10-25 2020-11-11 Nouscom Ag Eukaryotic cell line.
EP3706770A4 (en) * 2017-11-07 2021-10-27 Nektar Therapeutics Immunotherapeutic combination for treating cancer
CA3095216A1 (en) 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines
GB201910794D0 (en) * 2019-07-29 2019-09-11 Pirbright Inst Vaccine
CN112220921B (en) * 2020-08-25 2022-08-16 北京交通大学 Combined vaccine for respiratory syncytial virus infection
CN117304280B (en) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 Recombinant RSV F protein and application thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6511845B1 (en) * 1992-08-07 2003-01-28 Alan R. Davis Methods for producing an immune response against HIV-1
US6180398B1 (en) * 1996-07-12 2001-01-30 Virogeneitics Corporation Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
EP1636360A4 (en) * 2003-06-03 2006-11-08 Cell Genesys Inc Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
CA2993042A1 (en) 2004-01-23 2005-08-04 Msd Italia S.R.L. Chimpanzee adenovirus vaccine carriers
WO2007106404A2 (en) * 2006-03-10 2007-09-20 The Regents Of The University Of California Vaccine for viruses that cause persistent or latent infections
US20070292922A1 (en) * 2006-03-31 2007-12-20 Cell Genesys, Inc. Regulated expression of recombinant proteins from adeno-associated viral vectors
WO2008085502A2 (en) * 2007-01-05 2008-07-17 Inseron, Inc. A green fluorescent protein optimized for expression with self-cleaving polypeptides
GB0706914D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
WO2009025770A2 (en) * 2007-08-17 2009-02-26 Wyeth A heterologous prime-boost immunization regimen
CL2007002710A1 (en) * 2007-09-20 2008-01-04 Univ Pontificia Catolica Chile Immunogenic formulation that confers protection against infection or pathology caused by the respiratory syncytial virus (vrs) comprising an attenuated recombinant strain of mycobacterium; and use of the immunogenic formulation to prepare a vaccine to prevent, treat or attenuate infections of vrs.
US7863425B2 (en) * 2007-09-26 2011-01-04 Cornell University Compositions and methods for inhibiting Yersinia pestis infection
GB0823497D0 (en) * 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
ES2898235T3 (en) * 2009-02-02 2022-03-04 Glaxosmithkline Biologicals Sa Simian adenovirus nucleic acid and amino acid sequences, vectors containing them, and their uses
BRPI1011034A2 (en) * 2009-05-18 2016-03-15 Panacea Biotec Ltd recombinant modified vaccinia ankara virus (mva) -based influenza vaccine
US9095546B2 (en) * 2009-07-20 2015-08-04 National Health Research Institutes Human respiratory syncytial virus (RSV) vaccine
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
WO2012085936A2 (en) * 2010-12-20 2012-06-28 Panacea Biotech Ltd Recombinant respiratory syncytial virus plasmids and vaccines
US9125870B2 (en) * 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV

Also Published As

Publication number Publication date
LT2869841T (en) 2021-11-25
BR112014033077A2 (en) 2017-08-01
AU2013285398A1 (en) 2015-02-05
WO2014005643A1 (en) 2014-01-09
HUE056675T2 (en) 2022-02-28
ES2895070T3 (en) 2022-02-17
IL236414A0 (en) 2015-02-26
ZA201500102B (en) 2017-09-27
KR20150038010A (en) 2015-04-08
JP2015526403A (en) 2015-09-10
WO2014006191A1 (en) 2014-01-09
CA2878367A1 (en) 2014-01-09
US20240091338A1 (en) 2024-03-21
PT2869841T (en) 2021-10-28
CN104780937A (en) 2015-07-15
MX365391B (en) 2019-05-31
JP6244358B2 (en) 2017-12-06
SG11201408746XA (en) 2015-01-29
DK2869841T3 (en) 2021-10-25
US20180256704A1 (en) 2018-09-13
US20150209420A1 (en) 2015-07-30
MX2014016119A (en) 2015-09-23
EA201492230A1 (en) 2015-06-30

Similar Documents

Publication Publication Date Title
IN2014KN03063A (en)
MX2019013123A (en) Oral dosing of glp-1 compounds.
PL3207053T3 (en) Novel immunogenic peptides
EA201691078A1 (en) THERAPEUTIC PEPTIDES
MX342716B (en) Vaccines for use in the prophylaxis and treatment of influenza virus disease.
DK2940135T3 (en) Heterodimerized polypeptide
BR112014028476A2 (en) immunogenic fragment of a polypeptide, isolated polynucleotide, immunogenic pharmaceutical composition, methods for treating an infection, for generating an immune response in a subject, and for immunizing a subject
WO2013106834A3 (en) Immunogenic wt-1 peptides and methods of use thereof
MX2021004211A (en) Vaccine compositions.
HK1232156A1 (en) Stabilised silicate compositions and their use as antiperspirant compositions
EA201391183A1 (en) METHODS OF STRENGTHENING IMMUNOGENSPECIFIC IMMUNE RESPONSES WITH THE HELP OF VECTOR VECTIONS
IL251120B (en) Immunogenic/therapeutic glycoconjugate compositions and uses thereof
BR112013030395A2 (en) polypeptide, polynucleotide, vector, immunogenic composition, vaccine, and use of an immunogenic composition
HK1256033A1 (en) Use of peptides to stimulate the immune system
ZA201608487B (en) Dual adjuvant vaccine compositions, preparation and uses
TN2014000518A1 (en) Reassortant btv and ahsv vaccines
SG11201500980WA (en) Clostridium difficile polypeptides as vaccine
HK1254514A1 (en) Methods and compositions for enhancing immune response to vaccination
EP3313384A4 (en) Therapeutic immune modulation using noble gas compositions
HK1216715A1 (en) Novel hemoglobin-derived peptide based pharmaceutical compositions
PL3077512T3 (en) Immunogenic compositions and vaccines derived from bacterial surface receptor proteins
MX2021006543A (en) Vaccine.
CY1124712T1 (en) NOVEL priming-boost schemes involving polynucleotide-encoded immunogenic polypeptides
IL267680A (en) Immunogenic composition comprising cyaa-derived polypeptide promoting a th1/th17-oriented immune response
GB201106162D0 (en) Combination vaccine